MetaCap

ACADIA Pharmaceuticals Inc. (ACAD)

NASDAQ: ACADHealth CareBiotechnology: Pharmaceutical PreparationsUSD

17.11-0.48 (-2.73%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ACAD stock chart

Technical analysis

Key statistics

All statistics
52-week range
15.86 – 30.96
Day range
17.05 – 17.79
Volume / Avg
1.90M / 2.18M
Beta
—

52-week range

$15.86$30.96

ACAD stock today

ACADIA Pharmaceuticals (ACAD) closed at $17.11 on Nov 20, down 2.73% (-$0.48), versus the S&P 500's 3.70% decline. Shares are 44.7% below their 52-week high of $30.96, set on Aug 19, 2026 and 7.9% above the 52-week low of $15.86, near the bottom of the past year's range. ACAD is down 35.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 27.4%.

ACADIA Pharmaceuticals trades at 8.1x its trailing twelve-month earnings per share of $2.12. Its forward P/E of 15.8x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About ACADIA Pharmaceuticals

Company profile

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Ms. Catherine E. Owen Adams
Headquarters
San Diego, CA
Employees
796
IPO year
1985
Website
acadia.com

Financial highlights

Full financials

In fiscal 2025, ACADIA Pharmaceuticals generated $1.07 billion in revenue, up 11.9% from fiscal 2024, its 10th consecutive year of revenue growth. Net income was $391.0 million (+72.7% year over year), for a net margin of 36.5% versus a median of -34.7% in the prior 5 years. Gross margin was 91.7% (up from 91.5%) and operating margin 9.8%.

ACADIA Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$1.07B$957.80M$726.44M$517.24M$484.14M
Growth+11.87%+31.85%+40.45%+6.83%+9.60%
Net income$391.00M$226.45M$-61.29M$-215.97M$-167.87M
EPS (diluted)$2.30$1.36$-0.37$-1.34$-1.05

Analyst forecast

Forecast

Consensus (20 analysts)

buy

Avg. price target

$30.32+77.21%

  • Strong buy 4
  • Buy 10
  • Hold 5
  • Sell 1
  • Strong sell 0

Target range

Low $16.00High $38.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$0.26 vs $0.19
Surprise
+36.84%

ACAD news

All ACAD news

ACADIA Pharmaceuticals peers

Health Care sector
ACAD peer companies
CompanyPrice% ChgMarket capCompare
LEGNLegend Biotech Corporation ADR15.25-5.28%$2.96Bvs ACAD
DYNDyne Therapeutics Inc.15.50-3.31%$2.90Bvs ACAD
TLXTelix Pharmaceuticals Limited ADR8.37-3.90%$2.84Bvs ACAD
BHCBausch Health Companies Inc.8.22-3.97%$3.08Bvs ACAD
XERSXeris Biopharma Holdings Inc.16.97+2.11%$3.10Bvs ACAD
SLSSELLAS Life Sciences Group Inc.13.66-8.08%$2.78Bvs ACAD
VKTXViking Therapeutics Inc.24.77-4.14%$3.16Bvs ACAD
ABCLAbCellera Biologics Inc.9.69-7.45%$3.16Bvs ACAD

Indexes, lists and sector

ACADIA Pharmaceuticals stock FAQ

What is ACADIA Pharmaceuticals's stock price today?

ACAD last traded at $17.11 as of Nov 20, 4:00 PM EST, down 2.73% on the day. Prices are delayed at least 15 minutes.

What is ACAD's P/E ratio?

ACAD trades at a trailing P/E ratio of 8.07 and a forward P/E of 15.75.

Who is ACADIA Pharmaceuticals's CEO?

Ms. Catherine E. Owen Adams is the chief executive officer of ACADIA Pharmaceuticals Inc., which has about 796 employees.

What is the ACAD 52-week high?

The 52-week high for ACAD is $30.96 and the 52-week low is $15.86. The stock is currently 44.7% below its high.

Compare ACAD